TP53 Mutations as a Predictive Biomarker in High-Risk Breast Cancer

In this MEDtalk, Mari Eskild Rasmussen, PhD candidate at the Department of Clinical Science, University of Bergen, presents findings from the PETREMAC trial investigating personalized neoadjuvant treatment strategies in high-risk breast cancer. The study explores TP53 mutation status as a predictive biomarker and compares long-term outcomes with matched real-world data from the Norwegian Cancer Registry.